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Abstract

Background: A clinical case of an elderly patient with gastroesophageal reflux disease (GERD)
prompted research of proton pump inhibitor (PPI) use in older adults. PPIs are one of the top
prescribed medication classes among the elderly population. PPIs have generally been
considered safe but current research has found association between PPI use with multiple
adverse effects.
Case Description: An 88-year-old female patient was seen by her primary care provider for a
chief complaint of cough that persisted for 3 months. Her symptoms, history, and physical
assessment were consistent with moderate GERD and she was prescribed low-dose omeprazole
with intent to follow-up with her provider in 1 month.
Literature Review: Multiple studies, systematic reviews, and meta-analyses were examined to
determine risks associated with prolonged PPI use in the elderly population. Adverse effects
including dementia, bone fracture, and Clostridium difficile (C. diff) susceptibility were
discovered. Also, research found that PPIs are often inappropriately prescribed due to improper
indication and/or follow-up by providers.
Clinical Relevance: Provider awareness of PPI misuse may result in the reduction of
unfavorable clinical outcomes in older adults and promote appropriate PPI prescriptive practice.
Avoiding adverse drug effects in the elderly population will improve patient health and minimize
unnecessary healthcare costs.
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Background

E.L., an 88-year-old female, presented to her primary care clinic for complaint of
persistent cough over three months despite completing treatment for bronchitis. Her cough was
dry and nonproductive and typically worsened after eating and laying down at night. In addition
to her cough, the patient reported daily heartburn which required frequent treatment with overthe-counter (OTC) antacids. The patient’s subjective and objective assessment findings were
consistent with the diagnostic criteria for gastroesophageal reflux disease (GERD). She was
given lifestyle modification instructions and prescribed omeprazole 20 mg by mouth daily with
plans to follow-up with her provider in one month.
Proton pump inhibitors (PPIs), like omeprazole, are among the top 10 most frequently
prescribed therapeutic drug classes in the United States (Masclee, Sturkenboom, & Kuipers,
2014). Elderly patients aged 65 and greater represent the largest consumer group of PPIs and
most other drug classes (Hamzat et al., 2012). Additionally, one-third of older adults take more
than 5 prescribed medications and nearly 20% are prescribed more than 10 (Kennedy-Malone,
Fletcher, & Martin-Plank, 2014). Polypharmacy is a primary predictor for adverse drug
reactions which account for 10% of all emergency room visits and up to 17% of all hospital
admissions (Kennedy-Malone et al., 2014). Furthermore, age-related physiologic changes within
older adults make them prone to adverse drug reactions (Kennedy-Malone et al., 2014).
Knowing this, providers should exercise caution when introducing new medications to this
population and intend to prescribe the lowest dose with the shortest duration to achieve
therapeutic effect.
For many years PPIs were generally regarded as safe medications with very few adverse
effects. However, current research has associated dementia, bone fracture, vitamin and mineral
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deficiencies, and susceptibility to Clostridium difficile (C. diff) infections with prolonged PPI use
(Wijarnpreecha et al., 2016). Furthermore, several studies have determined that over 50% of PPI
prescriptions are inappropriate or require deprescribing (Bergamo et al., 2015). The purpose of
this report is to bring awareness to providers regarding potential adverse effects of prolonged PPI
use, proper prescribing of PPIs, and deprescribing initiatives in the elderly. Appropriately
balancing the indication, benefits, and harms of PPI therapy within this population can
significantly minimize avoidable adverse effects, morbidity, hospital admission, and healthcare
costs (Masclee et al., 2014).
Case Report
The following is the report of E.L.’s clinic visit that occurred on Friday, March 10, 2017
at the University of North Dakota’s New School of Medicine & Health Sciences building.
Vital Signs:
Temperature – 97.8° F
Pulse – 76
Respirations – 16
Blood pressure – 130/80 mmHg
Chief complaint: “Cough that won’t go away”
History of Presenting Illness:
This 88-year-old woman presents to the clinic with a chief complaint of a “cough that
won’t go away.” The patient states that the cough began approximately 3 months ago and has
persisted despite being treated for bronchitis 2 months ago. The cough is dry, nonproductive,
and is typically worse at nighttime when she lays down. The patient also notes that her cough is
worse after eating or drinking. To treat the cough, she sleeps with a humidifier in her bedroom
and sucks on throat lozenges throughout the day. However, these efforts have provided little to
no relief. The patient denies pain or sore throat with her cough.
She is currently prescribed Lisinopril for hypertension, she is unsure when it was initially
prescribed to her but states that she has been taking it for “a long time.” Also, she takes an overthe-counter antacid several times a day for post-meal heartburn.
Past Medical & Surgical History:
Essential (primary) hypertension – unknown date of diagnosis
Abdominal hernia – monitored by gastroenterology
Denies surgical history
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Current Medications:
Lisinopril 10 mg PO daily
Tums 2-4 tabs PO PRN with meals
Allergies:
No known drug allergies
Family History:
Positive immediate family history for heart disease, diabetes, and colon cancer – unknown
specificity of diseases to family member
Personal & Social History:
Former smoker
Consumes 1-2 alcoholic beverages nightly
Denies illicit drug use
Consumes 1 pot of coffee (8-12 servings) daily
Received influenza immunization this season – current on all other immunizations
Review of Systems:
General – denies fever, chills, night sweats, fatigue, and unintentional changes in body weight
HEENT – denies headache, sinus pressure, changes in vision or hearing, ear pain, nasal
discharge, and sore throat
Cardiac – denies chest pain or pressure, palpitations, and swelling in extremities
Respiratory – persistent, dry, & nonproductive cough; denies shortness of breath and dyspnea
Gastrointestinal – heartburn daily with meals; denies abdominal/pelvic pain, nausea/vomiting,
constipation/diarrhea, hematuria, blood in stool, incontinence, and difficulty voiding
Physical Exam:
General – well appearing, alert and oriented x3, normal mood and affect
Head – normocephalic, atraumatic, no pain in frontal or maxillary sinuses with palpation
Eyes – conjunctiva clear, sclera non-icteric, EOM intact, PERRLA
Ears – EACs clear, TMs translucent, normal light reflex, ossicles normal appearance
Nose – no external lesions, mucosa non-inflamed, septum and turbinates normal, no discharge
Mouth/Pharynx – mucous membranes moist, no mucosal lesions, no redness, no tonsillar
hypertrophy, no post-nasal drip
Neck – supple without lymphadenopathy
Heart – regular rate and rhythm, no murmur, no extra heart sounds, no rubs, no gallops
Lungs – clear and equal to auscultation without wheeze, rales, or rhonchi bilaterally
Abdomen – obese with soft, protruding, & reducible hernia in center of abdomen above
umbilicus; abdomen soft and non-distended, bowel sounds active in all quadrants, no tenderness
with palpation, no masses, no liver or spleen enlargement
Additional Laboratory Tests, Imaging, and/or Diagnostic Studies:
No additional studies necessary at this time
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Assessment/Diagnosis:
Gastroesophageal reflux disease (GERD)
Plan/Treatment:
1. Recommended the following lifestyle changes for prevention and treatment of GERD:
(Dunphy et al., 2015)
a. Elevate the head of the bed 6-8 inches when laying down
b. Avoid high-fat meals, large meals, and problematic foods such as chocolate,
alcohol, peppermint, caffeine, onions, citrus, and tomatoes
c. Avoid sleeping for 3-4 hours after a meal and avoid bedtime snacks
d. Weight loss as tolerated
2. Continue use of OTC Tums 2-4 tabs by mouth as needed for heartburn post meals
3. Start omeprazole 20 mg by mouth daily on an empty stomach
4. Follow-up in 1 month for reevaluation. Follow-up encouraged sooner for worsening
symptoms or additional questions and concerns.
The common symptoms of GERD are heartburn, regurgitation, dysphagia, coughing,
hoarseness, and nocturnal wheezing (Dunphy et al., 2015). Factors that exacerbate symptoms
include consuming trigger foods such as alcohol or caffeine, reclining after eating, and
aggravating body positions like heavy lifting or bending over (Dunphy et al., 2015). The
physical examination of GERD patients is usually normal and in 80% of cases the diagnosis is
made by history alone with no required laboratory tests or imaging (Dunphy et al., 2015).
Therefore, the diagnosis of GERD for E.L. is appropriate based on her reported history and
negative physical assessment.
E.L. has daily and persistent symptoms despite regular use of antacids. Step-up treatment
for persistent GERD include diet and lifestyle modifications and daily pharmacological therapy
with an H₂ receptor agonist (H₂RA) or low-dose PPI (Dunphy et al., 2015). These interventions
should be trialed for 8 weeks and then reevaluated to determine if step-down therapy is
appropriate (Dunphy et al., 2015). Since GERD is a new diagnosis for E.L., her provider will
follow-up with her in 1 month to monitor her progress.
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Literature Review

The prescription of omeprazole within this case report provoked research of adverse
effects associated with prolonged PPI use in the elderly as well as appropriate prescribing and
management of PPIs in this population. Since PPIs are among the most commonly prescribed
medications in the United States, a thorough understanding of these topics are necessary for
providers to effectively balance the indication, benefits, and harms of PPI use.
Indications for PPIs
According to Woo and Robinson (2016), “PPIs are indicated for erosive gastritis, GERD,
and Zollinger-Ellison syndrome and as part of a multidrug regimen for short-term treatment of
active peptic ulcer disease (PUD), especially duodenal ulcers caused by Helicobacter pylori” (p.
528). For treatment of uncomplicated gastric ulcers, a once daily dose of a PPI is indicated for
12 weeks (Woo & Robinson, 2016). In GERD management, PPIs are typically indicated once
daily for 8 weeks and only after lifestyle modifications and OTC antacids or H₂RAs have been
trialed (Woo & Robinson, 2016). PPI treatment is also appropriate for individuals with chronic
NSAID use or antiplatelet therapy with low-dose aspirin or clopidogrel (Bergamo et al., 2015).
Long-term PPI use is only recommended in patients with high risk of gastrointestinal bleeding,
Barrett’s esophagus, or Zollinger-Ellison syndrome (Wilsdon et al., 2017).
Inappropriate Use of PPIs in the Elderly
Inappropriate PPI use is determined when patients are prescribed PPIs for indications not
listed above or for a prolonged period of time. Multiple reviews have observed inappropriate
PPI prescription in 50-80% of patients admitted to and discharged from geriatric medicine wards
(Masclee et al., 2014). One study observed inappropriate continuation of PPIs in 67% of elderly
patients after in-hospital initiation for stress ulcer prophylaxis (Wilsdon et al., 2017). Another
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study observed that 50-60% of patients became chronic PPI users after treatment of H. pylori
(Masclee et al., 2014). Both studies display unsuitable use of PPIs due to lack of proper followup and/or deprescribing initiatives by providers.
Another cause for inappropriate PPI prescription in the elderly is seen in patients with
dementia history. In one study, 61% of the patient sample with dementia were inappropriately
prescribed PPIs (Hamzat et al., 2012). Significant cognitive impairment in this population may
reduce their ability to properly describe their medical history and reduce a provider’s ability to
properly diagnose and treat (Hamzat et al., 2012).
Adverse Effects of Long-term PPI Use
Since their introduction to the market PPIs have been regarded as safe and effective
medications with very few side effects. Mild adverse reactions such as nausea, abdominal pain,
constipation, and diarrhea are most frequently reported but mounting evidence demonstrates that
PPIs may be associated with more severe effects when overprescribed (Pastorino et al., 2015). In
fact, the Food and Drug Administration (FDA) has issued several warnings within the last seven
years regarding long-term PPI use.
In 2010 a change in labeling information for PPIs was indicated for warning of possible
increased fracture risk with long-term use (Masclee et al., 2014). In 2011 the FDA stated that
PPIs may cause low serum magnesium levels if taken for prolonged periods of time and
providers should consider monitoring magnesium levels before and during treatment (Pastorino
et al., 2015). Most recently, the FDA published a safety alert cautioning the association of PPIs
and C. diff infection in 2015 (Schoenfeld & Grady, 2016).
Dementia. In the last 10 to 15 years, numerous studies developed to determine the
association with prolonged PPI use and dementia prevalence. Dementia is one of the major
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disabilities among older adults and is characterized by cumulative cognitive decline and a
progressive inability to live independently (Gomm et al., 2016). In 2015, worldwide healthcare
costs associated with dementia rose to an estimated $818 billion from $604 billion in 2010
(Batchelor et al., 2017). Today, 46.8 million people worldwide have dementia and this figure is
expected to triple by the year 2050 (Batchelor et al., 2017).
PPIs are hypothesized to cause a decline in cognitive functioning through several
mechanisms. First, in vitro studies have shown that PPIs may interfere with degradation of
amyloid beta (Αβ) peptides resulting in increased Αβ levels, a pathological hallmark of
Alzheimer’s disease (Wijarnpreecha et al., 2016). Additionally, PPIs may inhibit lysosomal
acidification resulting in accumulation of protein aggregates causing vascular dysfunction and a
potential starting point for cognitive decline (Batchelor et al., 2017). Finally, presence of
vitamin B₁₂ deficiency is frequently reported in previous and current PPI users (Gomm et al.,
2016). “Poor vitamin B₁₂ status has been described as negatively affecting cognition and
promoting neurological damage, probably owing to impaired DNA synthesis, methylation, and
homocysteine neurotoxicity” (Gomm et al., 2016, p. 414). Chronic PPI use has been linked to a
46% decline in median serum B₁₂ levels and subnormal B₁₂ levels in 10% of patients (Abraham,
2012).
The most significant study associating PPI use with dementia examined data from the
largest German public health insurer covering one-third of the population (Gomm et al., 2016).
The study found statistically significant data associating prolonged PPI use with increased risk of
dementia in older adults age 75 and above (Gomm et al., 2016). A similar study used detailed
neuropsychological tests to establish the diagnosis of dementia and found a 1.4-fold increased
risk of any dementia in cohorts using PPIs (Batchelor et al., 2017). Also, a meta-analysis found
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a small but elevated risk of dementia among PPI users but it was not statistically significant
(Wijarnpreecha et al., 2016).
Bone Fracture. Older adults, especially elderly women, are at increased risk of bone
degeneration and fracture due to hormonal and other physiological age-related changes.
Efficient calcium absorption is essential for skeletal integrity but research has found that
prolonged PPI use may be associated with decreased calcium absorption (Hinson et al., 2015).
Prolonged PPI use has been linked to PPI-induced hypochlorhydria which causes impaired
calcium absorption and reduced calcium bioavailability (Hinson et al., 2015). Hypochlorhydria
results in compensatory and chronic hyperparathyroidism leading to increased bone turnover
(Hinson et al., 2015).
A systematic review evaluated 4 studies that discovered modest association between
high-dose PPI use and fractures of the hip, spine, wrist, and forearms (Hinson et al., 2015).
Individuals aged 50 and older who used PPIs for 1 year or longer were at greatest risk of fracture
(Hinson et al., 2015). Also, a meta-analysis of 18 observational studies found that PPI use was
associated with a 26% higher risk of hip fracture, a 58% higher risk of spine fracture, and a 33%
higher risk for fracture at any site (Schoenfeld & Grady, 2016). No studies have proven
association between long-term PPI use and low bone mineral density (BMD) but BMD findings
alone are not sufficient evidence to dismiss association of PPIs and fracture risk (Hinson et al.,
2015).
Clostridium difficile Susceptibility. Perhaps the most widely accepted data regarding
adverse effects from prolonged PPI use is found with C. diff susceptibility. Stomach acid
provides a natural defense against microbial pathogens but PPIs cause a reduction in gastric
acidity (Woo & Robinson, 2016). Reduction in gastric acidity may promote bacterial
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overgrowth in the gastrointestinal tract thus increasing the risk of C. diff infection (Schoenfeld &
Grady, 2016). Also, bacterial overgrowth and colonization within the small intestine can result
in malabsorption of fat, carbohydrate, protein, and micronutrients leading to diarrhea and
malnutrition (Teramura-Grönblad et al., 2010). Individuals that acquire C. diff, a toxinproducing pathogen that is damaging to the bowel mucosa, often require hospital management
for dehydration and/or malnutrition and have prolonged hospital stays (Dunphy et al., 2015).
One meta-analysis of 5 studies found that C. diff-associated diarrhea in elderly PPI users
also on broad spectrum antibiotics increased 2- to 3-fold (Abraham, 2012). A more recent metaanalysis of 39 studies mirrored these findings and determined a 74% higher risk of developing C.
diff infection and a 2.5-fold higher risk of reoccurring C. diff infection among PPI users versus
nonusers (Schoenfeld & Grady, 2016).
Another study found elderly nursing home patients on PPIs had 19.7% increased
incidence of diarrhea than nonusers (Teramura-Grönblad et al., 2010). Diarrhea is often
considered a mild medication side effect but it cannot be overlooked in nursing home patients.
“In this frail elderly population dependent on other people’s continuous help, frequent diarrhea is
a burdensome symptom causing unnecessary suffering and skin problems” (Teramura-Grönblad
et al., 2010, p. 157). Other potential complications of diarrhea include dehydration, malnutrition,
peritonitis, sepsis, shock, anemia, and/or electrolyte imbalances (Kennedy-Malone et al., 2014).
Implications for Practice
Unfortunately, research regarding adverse effects of prolonged PPI use in the elderly
population is preliminary and results are varied or inconsistent. The results are commonly
critiqued and questioned due to suspicion of bias, disregard for comorbidities and/or
comedications, lack of ethnic diversity, or inconsistent diagnostic tools. Thus, no new practice
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guidelines regarding safe PPI prescription in the elderly have been prompted from these studies.
Nonetheless, providers should be cognizant of these potential adverse effects and utilize
every opportunity to evaluate appropriate indication of use of PPIs. Batchelor et al. (2017)
suggests that “meticulous risk-benefit analysis when prescribing PPIs should be considered in all
cases, especially among older patient populations” (p. 17). Furthermore, deprescribing of PPIs
should be initiated whenever clinically appropriate.
Deprescribing is the process of withdrawing an inappropriate medication with the goal to
manage burdens of medication and improve outcomes (Wilsdon et al., 2017). For example, a
step-down approach to an OTC H₂RA should be initiated after 8 weeks of PPI therapy in patients
with moderate GERD (Woo & Robinson, 2016). However, there are several barriers to
deprescribing PPIs including concern for return of symptoms, lack of patient knowledge of
deprescribing necessity, and lack of provider initiation (Wilsdon et al., 2017).
Wilsdon et al. (2017) conducted a systematic review of 21 studies to evaluate effective
strategies for deprescribing inappropriate PPIs in older adults. Strategies included nationwide
public educational campaigns, pharmacist-led interventions, distribution of educational
brochures to patients, and education seminars for hospital clinicians. Many approaches were
successful at decreasing inappropriate PPI prescriptions but in the end, the authors recommended
that healthcare providers utilize a common-sense approach when reviewing patient medications
(Wilsdon et al., 2017). Ultimately, it is the provider’s responsibility to be familiar with potential
adverse effects associated with prolonged PPI use and to be vigilant in their prescribing habits
(Abraham, 2012).
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Learning Points

In conclusion, chronic use of PPIs in the elderly population has caused uncertainty
regarding potential adverse effects associated with their long-term or inappropriate use. Multiple
risks have been linked to prolonged PPI use and greater attention must be paid to protect older
adults from unnecessary harm and to cut healthcare costs (Bergamo et al., 2015). Providers
should consider the following facts when prescribing PPIs:
•

The elderly population represents the largest group of consumers of PPIs and other
medications. Also, they have an elevated risk for adverse drug reactions resulting in
hospital admissions and increased healthcare expenditures.

•

The use of PPIs in older adults is often prolonged or unnecessary due to inappropriate
prescribing and/or monitoring by providers.

•

Overuse of PPIs has been linked to multiple adverse effects in the elderly population
including dementia, bone fracture, and C. diff susceptibility. Unfortunately, studies
regarding these effects are inconsistent so no changes in practice have been warranted at
this time.

•

It is the provider’s responsibility to recognize the potential risks associated with
prolonged PPI use. They must exercise caution when prescribing PPIs to the elderly and
ensure proper indication and follow-up to prevent misuse.
Providers should discuss the potential benefits and risks of PPI use with each patient and

individualize treatment to achieve optimal clinical outcomes. With this practice and
acknowledgement of the facts listed above, PPI-related adverse effects in the elderly population
may be reduced significantly and unnecessary burdens on the healthcare system avoided.
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